Heartsine Technologies
Crescent Capital Initial Investment 2000
Crescent Capital first invested in this company in December 2000 before the first product prototype was completed. ACT Ventures joined Crescent in a second round which raised £2m in March 2002.
HeartSine Technologies, Inc was established in 1997 as a medical device development company focusing on defibrillation technology. It is based on research carried out in the Northern Ireland Bio-Engineering Centre at the University of Ulster. The parent company is based in the US with a N.I. subsidiary, which at present is the main operating base.
The company developed new defibrillators that automatically deliver a controlled electrical shock to restart the heart in the event of a sudden cardiac arrest (SCA). These devices, known as Automated External Defibrillators (”AEDs”), are designed for use by lesser-trained emergency responders or first aiders. Heartsine’s first product, the Samaritan, was launched in the European market at the Ambex show in June 2002. A more compact defibrillator, known as the PAD, we launched in 2004 and is now the company’s leading product.
This has now obtained FDA approval in the US and sales have begun in both the US and European markets.
HeartSine is also working on other products. Of particular interest is an implantable device to manage atrial fibrillation, a common problem in elderly people. It is hoped that initial trials on this product will begin later this year.
The driving forces behind the business all have considerable experience in medical devices and particularly in the defibrillation sector. This experience covers the major disciplines of technology, manufacturing/engineering and marketing.
Contact Details
Crescent Contact : Colin Walsh
Canberra House
204 Airport Road West
Belfast, BT3 9ED
Tel: +44 (0) 28 9053 4210
Fax: +44 (0) 28 9053 4211
Professor John Anderson Heartsine Technologies
Professor John Anderson is a founder of Heartsine Technologies and serves as Chief Technology Officer and a Director. He is presently Head of School, Electrical and Mechanical Engineering, University of Ulster, Jordanstown, Northern Ireland. He was the head of BioEngineering at the Royal Victoria Hospital in NI, when the world’s first mobile coronary care unit was launched in 1967. Later he was responsible for the development of the worlds first truly portable defibrillator designed for use outside of the hospital, which was subsequently manufactured and sold throughout the world.
Crescent Capital NI Ltd is authorised and regulated by the Financial Services Authority
Crescent Capital NI Ltd is a member of the EVCA